Compare Smith & Nephew plc (SNN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Teladoc Health Inc — how do they compare? Smith & Nephew plc trades at $29.68 (market cap $12.54B), while Teladoc Health Inc trades at $6.64 (market cap $1.24B). The key difference: Smith & Nephew plc is far larger — about 10.1× Teladoc Health Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| SNN | TDOC | |
|---|---|---|
Market Cap | $12.54B | $1.24B |
Sector | Health | Health |
52-Week High | $38.70 | $9.72 |
52-Week Low | $28.73 | $4.47 |
Enterprise Value | $15.57B | $1.50B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Teladoc Health (TDOC) trades at $7.08, down 0.7% for the day, with a bearish technical signal and negative earnings. The stock faces pressure from a recent 28% drop after Q2 2026 revenue missed estimates and full-year guidance was cut. Valuation metrics like P/S of 0.49 and EV/EBITDA of 6.96 appear low, but profitability remains weak with a -7.13% net income margin. Multiple law firms are investigating potential securities violations, adding to investor concerns.
The outlook is cautious due to ongoing losses and competitive pressures in virtual care. Risks include execution challenges at the BetterHelp unit and regulatory scrutiny. Analyst consensus is mixed with a $8.88 price target, but near-term volatility is likely amid negative sentiment and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
